



Correction

Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

The *PLOS ONE* Staff

Notice of Republication

This article was republished on September 15, 2014, to correct typesetting errors involving missing minus symbols throughout the text and tables. The publisher apologizes for these errors. Please download this article again to view the article. The originally published, uncorrected article and the republished, corrected article are provided here for reference.

Supporting Information

File S1. Originally published, uncorrected article (PDF)

File S2. Republished, corrected article (PDF)

Reference

1. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, et al. (2014) Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. *PLoS ONE* 9(8): e105638. doi:10.1371/journal.pone.0105638

Citation: The *PLOS ONE* Staff (2014) Correction: Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes. *PLoS ONE* 9(9): e110069. doi:10.1371/journal.pone.0110069

Published September 30, 2014

Copyright: © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.